MGMT autoantibodies as a potential prediction of recurrence and treatment response biomarker for glioma patients.

ABSTRACT:

Background

Cancer-specific autoantibodies found in serum of cancer patients have been characterized as potential predictors of the high risk of recurrence and treatment response. The objective of this study is to investigate the clinical utility of serum O-6-methylguanine-DNA methyltransferase (MGMT) autoantibodies as novel biomarkers for prediction of recurrence and treatment response for glioma through MGMT peptides microarray.

Methods

A total of 201 serum samples of glioma patients with various WHO grade and 311 serum samples of healthy donors were examined for the detection of MGMT autoantibodies by peptides microarray. The clinical value of MGMT autoantibodies was studied through univariable and multivariable analyses.

Results

Autoantibodies to MGMT peptides were

SUBMITTER: Wu H 

PROVIDER: S-EPMC6675704 | biostudies-literature | 2019 Aug

REPOSITORIES: biostudies-literature